1. Dental material comprising a radically polymerizable organic binder, at least one initiator for the radical polymerization and at least one accelerator for the radical polymerization, wherein both initiator and accelerator each have at least one radically polymerizable group.
2. Dental material according to claim 1, in which the binder contains monomers andor oligomers with two or more radically polymerizable groups.
3. Dental material according to claim 2, in which the binder contains at least one polysiloxane with radically polymerizable groups.
4. Dental material according to claim 2, in which the binder contains at least one dendrimer which has radically polymerizable groups.
5. Dental material according to claim 2, in which the binder contains at least one radically polymerizable crossliniking monomer.
6. Dental material according to claim 2, in which the binder contains exclusively radically polymerizable monomers andor oligomers with two or more radically polymerizable groups.
7. Dental material according to claim 1, which contains a photoinitiator.
8. Dental material according to claim 1, which contains as initiator at least one alpha-diketone, one azo compound, one peroxide, one benzildimethylketal, one benzoin ether, one dialkoxyacetophenone andor one trimethylbenzoyl phosphine oxide.
9. Dental material according to claim 1, which contains as accelerator an amine, a barbituric acid derivative or a sulfinic acid derivative.
10. Dental material according to claim 1, which additionally contains at least one UV absorber which has at least one radically polymerizable group.
11. Dental material according to claim 1, which additionally contains at least one inhibitor for the radical polymerization which has at least one radically polymerizable group.
12. Dental material according to claim 1, which additionally contains an anti-oxidant which has at least one radically polymerizable group.
13. Dental material according to claim 1, which contains a UV stabilizer and an inhibitor which both have one radically polymerizable group.
14. Dental material according to claim 1, which contains no non-radically polymerizable monomeric or polymeric constituents.
15. Dental material according to claim 1, which contains no solvent.
16. Dental material according to claim 1, which additionally contains filler.
17. Dental material according to claim 16, in which the filler is surface-modified with an adhesion promoter.
18. Dental material according to claim 17, in which the adhesion promoter has at least one radically polymerizable group.
19. Dental material according to claim 1, which additionally contains one or more pigments.
20. Dental material according to claim 19, which, apart from pigments and filler, contains exclusively components which have radically polymerizable groups.
21. Dental material according to claim 1, which contains
(a) 1 to 50 wt.-%, in particular 5 to 40 wt.-% of binder,
(b) 0.1 to 5.0 wt.-%, in particular 0.2 to 2.0 wt.-% of initiator,
(c) 0.1 to 5.0 wt.-%, in particular 0.2 to 2.0 wt.-% of accelerator in each case relative to the total mass of the material.
22. Dental material according to claim 21, which additionally contains (d) 0.01 to 3.0 wt.-%, in particular 0.05 to 2.0 wt.-% of inhibitor, relative to the total mass of the material.
23. Dental material according to claim 21, which additionally contains (e) 0 to 90, in particular 3 to 80 wt.-% of filler, relative to the total mass of the material.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method of treating a pathological condition in a patient in which endogenous 2-arachidonoylglycerol (2-AG) and endogenous 1(3)-arachidonoylglycerol or any other substrate metabolized by the monoacyl glycerol lipase (MGL) enzyme are involved comprising administering to said patient a therapeutically effective amount of a compound of formula (I):
in which:
A and X are, independently of one another, nitrogen or CH;
R1 is an aryl or heteroaryl group optionally substituted with one or more groups selected from halogen, (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy and halo(C1-C6)alkoxy; and
R2 is an aryl group optionally substituted with one or more groups selected from halogen, methyl, trifluoromethyl, methoxy and trifluoromethoxy; or
a pharmaceutically acceptable salt thereof.
2. The method according to claim 1, wherein for the compound of formula (I):
A is nitrogen; and
X is CH.
3. The method according to claim 1, wherein for the compound of formula (I):
R1 is an aryl or heteroaryl group optionally substituted with one or more groups selected from halogen, (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy and halo(C1-C6)alkoxy.
4. The method according to claim 1, wherein for the compound of formula (I):
R1 is phenyl, furan, thiophene or naphthalene, optionally substituted with halogen.
5. The method according to claim 1, wherein the compound is selected from the group consisting of:
5-(2-chlorophenyl)1,2,3triazolo4,5-bpyridin-3-yl4-(3-trifluoromethylphenyl)piperazin-1-ylmethanone;
5-(3-chlorophenyl)1,2,3triazolo4,5-bpyridin-3-yl4-(3-trifluoromethylphenyl)piperazin-1-ylmethanone;
5-(4-chlorophenyl)1,2,3triazolo4,5-bpyridin-3-yl4-(3-trifluoromethylphenyl)piperazin-1-ylmethanone;
(5-furan-3-yl1,2,3triazolo4,5-bpyridin-3-yl)4-(3-trifluoromethylphenyl)piperazin-1-ylmethanone;
(5-thiophen-3-yl1,2,3triazolo4,5-bpyridin-3-yl)4-(3-trifluoromethylphenyl)piperazin-1-ylmethanone;
(5-naphthalen-2-yl1,2,3triazolo4,5-bpyridin-3-yl)4-(3-trifluoromethylphenyl)piperazin-1-ylmethanone; and
(5-naphthalen-1-yl1,2,3triazolo4,5-bpyridin-3-yl)4-(3-trifluoromethylphenyl)piperazin-1-ylmethanone.
6. A method of treating a pathological condition in a patient in which endogenous anandamide or any other substrate metabolized by the Fatty Acid Amide Hydrolase (FAAH) enzyme is involved comprising administering to said patient a therapeutically effective amount of a compound of formula (I):
in which:
A and X are, independently of one another, nitrogen or CH;
R1 is an aryl or heteroaryl group optionally substituted with one or more groups selected from halogen, (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy and halo(C1-C6)alkoxy; and
R2 is an aryl group optionally substituted with one or more groups selected from halogen, methyl, trifluoromethyl, methoxy and trifluoromethoxy; or
a pharmaceutically acceptable salt thereof.
7. The method according to claim 6, wherein for the compound of formula (I):
A is nitrogen; and
X is CH.
8. The method according to claim 6, wherein for the compound of formula (I):
R1 is an aryl or heteroaryl group optionally substituted with one or more groups selected from halogen, (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy and halo(C1-C6)alkoxy.
9. The method according to claim 6, wherein for the compound of formula (I):
R1 is phenyl, furan, thiophene or naphthalene, optionally substituted with halogen.
10. The method according to claim 6, wherein the compound is selected from the group consisting of:
5-(2-chlorophenyl)1,2,3triazolo4,5-bpyridin-3-yl4-(3-trifluoromethylphenyl)piperazin-1-ylmethanone;
5-(3-chlorophenyl)1,2,3triazolo4,5-bpyridin-3-yl4-(3-trifluoromethylphenyl)piperazin-1-ylmethanone;
5-(4-chlorophenyl)1,2,3triazolo4,5-bpyridin-3-yl4-(3-trifluoromethylphenyl)piperazin-1-ylmethanone;
(5-furan-3-yl1,2,3triazolo4,5-bpyridin-3-yl)4-(3-trifluoromethylphenyl)piperazin-1-ylmethanone;
(5-thiophen-3-yl1,2,3triazolo4,5-bpyridin-3-yl)4-(3-trifluoromethylphenyl)piperazin-1-ylmethanone;
(5-naphthalen-2-yl1,2,3triazolo4,5-bpyridin-3-yl)4-(3-trifluoromethylphenyl)piperazin-1-ylmethanone; and
(5-naphthalen-1-yl1,2,3triazolo4,5-bpyridin-3-yl)4-(3-trifluoromethylphenyl)piperazin-1-ylmethanone.
11. A method of treating a disease selected from the group consisting of an inflammatory disease, dizziness, eating disorders, metabolic syndrome, dyslipidemia, epilepsy, a sleep disorder, osteoporosis, an ocular condition, a pulmonary condition, a gastrointestinal disease, urinary incontinence, and bladder inflammation, comprising administering to said patient a therapeutically effective amount of a compound of formula (I):
in which:
A and X are, independently of one another, nitrogen or CH;
R1 is an aryl or heteroaryl group optionally substituted with one or more groups selected from halogen, (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy and halo(C1-C6)alkoxy; and
R2 is an aryl group optionally substituted with one or more groups selected from halogen, methyl, trifluoromethyl, methoxy and trifluoromethoxy; or
a pharmaceutically acceptable salt thereof.
12. The method according to claim 11 wherein the disease is an inflammatory disease.
13. The method according to claim 11 wherein the disease is dizziness.
14. The method according to claim 11 wherein the disease is selected from the group consisting of eating disorders, metabolic syndrome and dyslipidemia.
15. The method according to claim 11 wherein the disease is selected from the group consisting of epilepsy and a sleep disorder.
16. The method according to claim 11 wherein the disease is osteoporosis.
17. The method according to claim 11 wherein the disease is selected from the group consisting of an ocular condition and a pulmonary condition.
18. The method according to claim 11 wherein the disease is selected from the group consisting of a gastrointestinal disease, urinary incontinence and bladder inflammation.